Vibeke Wewer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vibeke Wewer has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Mikkel Malham
Department of Paediatrics and Adolescent Medicine Hvidovre Hospital, University of Copenhagen Hvidovre Denmark
5 shared publications - Johan Burisch
Gastro Unit Medical Section Copenhagen University Hospital—Amager and Hvidovre Hvidovre Denmark
4 shared publications - Mads Damsgaard Wewer
Gastro Unit, Medical Section, Copenhagen University Hospital - Amager and Hvidovre 5 , Hvidovre
3 shared publications - Christian Jakobsen
Department of Pediatric and Adolescent Medicine Amager‐Hvidovre University Hospital, Copenhagen IBD Center Copenhagen Denmark
2 shared publications - Paal Skytt Andersen
Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark
2 shared publications - Rie Louise Møller Nordestgaard
Gastrounit, Medical Division Copenhagen University Hospital—Amager and Hvidovre Hvidovre Denmark
2 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Association of attention‐deficit/hyperactivity disorder and autism with inflammatory bowel disease activity
Objectives: To estimate the effect of attention deficit hyperactivity disorder (ADHD) and autism on the disease activity of inflammatory bowel disease (IBD) in pediatric and young patients. Methods: Patients diagnosed with IBD between the ages of 6 and 24 years were identified in Danish nationwide registries 1996–2022. Cumulative incidences for severe disease activity (defined as advanced therapies, oral corticosteroids, IBD‐related surgery and hospitalization) were estimated and compared between patients with IBD with and without ADHD/autism. Cox regression analysis was used to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for each of the severe events. Results: A total of 785 patients with IBD and ADHD/autism and 6729 patients with IBD only were included. ADHD and autism were associated with a higher cumulative incidence of severe disease activity (10‐year cumulative incidence: 36.2% vs. 33.7%). When investigating each severe event, ADHD and autism were associated with a higher risk of receiving advanced IBD therapies (aHR: 1.2, 95% CI: 1.0–1.3). Patients with ulcerative colitis and ADHD/autism had a higher risk for colectomy (aHR: 1.4, 95% CI: 1.0–1.8), especially those diagnosed with IBD before 18 years of age (aHR: 1.7, 95% CI: 1.1–2.6). Conclusions: ADHD and autism were associated with more severe IBD disease activity in pediatric and young patients. Although mainly smaller effects were observed, the findings may inform targeted efforts for patients with ADHD/autism and IBD to reduce the likelihood of severe disease activity.
- 8 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessAssociation of attention‐deficit/hyperactivity disorder and autism with inflammatory bowel disease activity
Objectives: To estimate the effect of attention deficit hyperactivity disorder (ADHD) and autism on the disease activity of inflammatory bowel disease (IBD) in pediatric and young patients. Methods: Patients diagnosed with IBD between the ages of 6 and 24 years were identified in Danish nationwide registries 1996–2022. Cumulative incidences for severe disease activity (defined as advanced therapies, oral corticosteroids, IBD‐related surgery and hospitalization) were estimated and compared between patients with IBD with and without ADHD/autism. Cox regression analysis was used to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for each of the severe events. Results: A total of 785 patients with IBD and ADHD/autism and 6729 patients with IBD only were included. ADHD and autism were associated with a higher cumulative incidence of severe disease activity (10‐year cumulative incidence: 36.2% vs. 33.7%). When investigating each severe event, ADHD and autism were associated with a higher risk of receiving advanced IBD therapies (aHR: 1.2, 95% CI: 1.0–1.3). Patients with ulcerative colitis and ADHD/autism had a higher risk for colectomy (aHR: 1.4, 95% CI: 1.0–1.8), especially those diagnosed with IBD before 18 years of age (aHR: 1.7, 95% CI: 1.1–2.6). Conclusions: ADHD and autism were associated with more severe IBD disease activity in pediatric and young patients. Although mainly smaller effects were observed, the findings may inform targeted efforts for patients with ADHD/autism and IBD to reduce the likelihood of severe disease activity.
- Open Access
- 1 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Anaemia in patients diagnosed with paediatric‐onset inflammatory bowel disease: A Danish nationwide cohort study
Objectives: Anaemia impairs daily activities and quality of life in patients with paediatric‐onset inflammatory bowel disease (PIBD). This study aimed to investigate the prevalence of anaemia at PIBD‐diagnosis and the following 5 years. Furthermore, anaemia subtypes and the association between anaemia and disease activity were assessed over time. Methods: Patients (6–17 years) diagnosed with PIBD between 2014 and 2022 were identified from Danish national health registers. Anaemia was defined according to the World Health Organization criteria. Anaemia subtypes (iron deficiency anaemia [IDA], anaemia of chronic disease [ACD], and IDA + ACD) were classified using guidelines by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. PIBD disease activity was based on medication, surgeries, and hospitalisation. Results: Of 1266 incident patients with PIBD, 660 (52%) were anaemic at diagnosis, decreasing to 25% in year 5. Moderate anaemia was most frequent at diagnosis and in the first year, while mild anaemia was more frequent in the following years. Of patients with anaemia at diagnosis, 237 were assigned a subtype; 25 (11%) presented with IDA, 44 (19%) with ACD, and 168 (71%) with IDA + ACD. Anaemia was associated with disease activity during the 5 years following PIBD‐diagnosis with a peak association in year 4 (adjusted risk ratio: 2.3; 95% confidence interval [CI]: 1.8–3.0). Conclusions: Anaemia was common at PIBD‐diagnosis and, although the prevalence decreased over time, especially mild anaemia, remained frequent. IDA + ACD was the most common subtype at diagnosis and disease activity was associated with anaemia.
- 1 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessAnaemia in patients diagnosed with paediatric‐onset inflammatory bowel disease: A Danish nationwide cohort study
Objectives: Anaemia impairs daily activities and quality of life in patients with paediatric‐onset inflammatory bowel disease (PIBD). This study aimed to investigate the prevalence of anaemia at PIBD‐diagnosis and the following 5 years. Furthermore, anaemia subtypes and the association between anaemia and disease activity were assessed over time. Methods: Patients (6–17 years) diagnosed with PIBD between 2014 and 2022 were identified from Danish national health registers. Anaemia was defined according to the World Health Organization criteria. Anaemia subtypes (iron deficiency anaemia [IDA], anaemia of chronic disease [ACD], and IDA + ACD) were classified using guidelines by the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition. PIBD disease activity was based on medication, surgeries, and hospitalisation. Results: Of 1266 incident patients with PIBD, 660 (52%) were anaemic at diagnosis, decreasing to 25% in year 5. Moderate anaemia was most frequent at diagnosis and in the first year, while mild anaemia was more frequent in the following years. Of patients with anaemia at diagnosis, 237 were assigned a subtype; 25 (11%) presented with IDA, 44 (19%) with ACD, and 168 (71%) with IDA + ACD. Anaemia was associated with disease activity during the 5 years following PIBD‐diagnosis with a peak association in year 4 (adjusted risk ratio: 2.3; 95% confidence interval [CI]: 1.8–3.0). Conclusions: Anaemia was common at PIBD‐diagnosis and, although the prevalence decreased over time, especially mild anaemia, remained frequent. IDA + ACD was the most common subtype at diagnosis and disease activity was associated with anaemia.
- 8 July 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (4) , 525-526
Editorial: Treatments for inflammatory bowel disease across age‐spectrum—Are they the same? Authors' reply
LINKED CONTENT: This article is linked to Nordestgaard et al papers. To view these articles, visit https://doi.org/10.1111/apt.18106 and https://doi.org/10.1111/apt.18143
- 8 July 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (4) , 525-526
Editorial: Treatments for inflammatory bowel disease across age‐spectrum—Are they the same? Authors' reply
LINKED CONTENT: This article is linked to Nordestgaard et al papers. To view these articles, visit https://doi.org/10.1111/apt.18106 and https://doi.org/10.1111/apt.18143
- Open Access
- 10 June 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (4) , 457-468
Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
Summary: Background: Paediatric‐onset and elderly‐onset inflammatory bowel disease (IBD) present unique treatment challenges.Aims: We investigated treatment patterns following a first and second course of systemic steroids in paediatric‐ and elderly‐onset IBD and compared them to adult‐onset IBD.Methods: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan–Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid‐sparing medications.Results: 1851 CD (13%) and 1687 (6%) UC patients were paediatric‐onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly‐onset. Paediatric‐onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52–1.77, UC: HR: 2.29, CI: 2.02–2.61] and biologics [CD: HR: 1.43, CI: 1.25–1.65, UC: HR: 1.27, CI: 0.99–1.64], while elderly‐onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35–0.44, UC: HR: 0.58, CI: 0.50–0.67] and biologics [CD: HR: 0.19, CI: 0.14–0.25, UC: HR: 0.36, CI: 0.27–0.48] compared to adult‐onset age groups. After two courses of systemic steroids, elderly‐onset still received less steroid‐sparing medications. High frailty was associated with lower usage of medications for elderly‐onset.Conclusion: There are significant differences in the use of steroid‐sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly‐onset IBD.
- 10 June 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (4) , 457-468
Open AccessTreatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
Summary: Background: Paediatric‐onset and elderly‐onset inflammatory bowel disease (IBD) present unique treatment challenges.Aims: We investigated treatment patterns following a first and second course of systemic steroids in paediatric‐ and elderly‐onset IBD and compared them to adult‐onset IBD.Methods: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan–Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid‐sparing medications.Results: 1851 CD (13%) and 1687 (6%) UC patients were paediatric‐onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly‐onset. Paediatric‐onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52–1.77, UC: HR: 2.29, CI: 2.02–2.61] and biologics [CD: HR: 1.43, CI: 1.25–1.65, UC: HR: 1.27, CI: 0.99–1.64], while elderly‐onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35–0.44, UC: HR: 0.58, CI: 0.50–0.67] and biologics [CD: HR: 0.19, CI: 0.14–0.25, UC: HR: 0.36, CI: 0.27–0.48] compared to adult‐onset age groups. After two courses of systemic steroids, elderly‐onset still received less steroid‐sparing medications. High frailty was associated with lower usage of medications for elderly‐onset.Conclusion: There are significant differences in the use of steroid‐sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly‐onset IBD.
- Open Access
- 3 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.
- 3 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessIdentification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.
- Open Access
- 11 May 2022
- Published by Hindawi Limited in GastroHep
- Vol. 2022, 1-11
Incidence, Disease Course, and Medical Treatment of a Danish Population-Based Cohort of Very Early-Onset Inflammatory Bowel Disease
Background and Aims. In very early-onset IBD patients (VEO-IBD), studies have shown an incidence ranging from 0.4 to 2.1/100,000, extensive disease location, and a corresponding difficult and debatable treatment. We therefore aimed to investigate the incidence and medical and surgical treatment of VEO-IBD in a well-defined Danish population-based cohort. Methods. All VEO-IBD patients, defined as an IBD diagnosis before 6 years of age, were included from the Capital Region and the Zealand Region in 2015-2020. Demographic and clinical data including medical and surgical treatment were systematically extracted from the patient files. Results. Forty VEO-IBD patients were identified, 11 diagnosed with CD, 23 UC, and 6 IBD-U. The incidence rate of VEO-IBD was 2.0/100,000 (95 CI 0.8-5.9). All VEO-IBD patients except one had extensive colonic involvement or pancolitis. A total of 34 (85.0) and 23 (57.5) of the VEO-IBD patients received immunomodulators and/or biologicals, respectively. The cumulative risks of receiving immunomodulators and/or biologicals after 1/3/5 years was 55.3/86.8/90.1 and 36.8/45.9/57.0, respectively. During follow-up, six VEO-IBD patients (15.0) were treated with vedolizumabalthough off-label for this age groupas second-line biological therapy. Four patients (17.4) with UC had a colectomy. Two colectomised patients were treated with vedolizumab. Conclusion. Our population-based study showed an incidence of VEO-IBD comparable with the incidence in other countries. The population were treated intensively with immunomodulators and biologicalsincluding off-label vedolizumaband compared to other studies had the same risk of undergoing IBD-related surgeries.
- 11 May 2022
- Published by Hindawi Limited in GastroHep
- Vol. 2022, 1-11
Open AccessIncidence, Disease Course, and Medical Treatment of a Danish Population-Based Cohort of Very Early-Onset Inflammatory Bowel Disease
Background and Aims. In very early-onset IBD patients (VEO-IBD), studies have shown an incidence ranging from 0.4 to 2.1/100,000, extensive disease location, and a corresponding difficult and debatable treatment. We therefore aimed to investigate the incidence and medical and surgical treatment of VEO-IBD in a well-defined Danish population-based cohort. Methods. All VEO-IBD patients, defined as an IBD diagnosis before 6 years of age, were included from the Capital Region and the Zealand Region in 2015-2020. Demographic and clinical data including medical and surgical treatment were systematically extracted from the patient files. Results. Forty VEO-IBD patients were identified, 11 diagnosed with CD, 23 UC, and 6 IBD-U. The incidence rate of VEO-IBD was 2.0/100,000 (95 CI 0.8-5.9). All VEO-IBD patients except one had extensive colonic involvement or pancolitis. A total of 34 (85.0) and 23 (57.5) of the VEO-IBD patients received immunomodulators and/or biologicals, respectively. The cumulative risks of receiving immunomodulators and/or biologicals after 1/3/5 years was 55.3/86.8/90.1 and 36.8/45.9/57.0, respectively. During follow-up, six VEO-IBD patients (15.0) were treated with vedolizumabalthough off-label for this age groupas second-line biological therapy. Four patients (17.4) with UC had a colectomy. Two colectomised patients were treated with vedolizumab. Conclusion. Our population-based study showed an incidence of VEO-IBD comparable with the incidence in other countries. The population were treated intensively with immunomodulators and biologicalsincluding off-label vedolizumaband compared to other studies had the same risk of undergoing IBD-related surgeries.
- Open Access
- 22 March 2022
- Published by Hindawi Limited in GastroHep
- Vol. 2022, 1-11
Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment
Background. Recent epidemiological studies in inflammatory bowel disease (IBD) indicate that paediatric onset of IBD (pIBD) more often requires biological therapy compared to adult onset of IBD (aIBD). Whether this is due to a more aggressive disease phenotype or lower threshold of prescribing biologicals is unknown. In order to expand these findings in a clinical setting, we compared the inflammatory burden in pIBD and aIBD patients requiring biological therapy. Methods. We retrospectively included 70 pIBD and 83 aIBD patients initiating biological therapy. Symptoms and biomarker levels were recorded prior to and 6, 14, 22, and 52 weeks after initiation of biological therapy. Results. In Crohn’s disease (CD), the baseline levels of faecal calprotectin and C-reactive protein (CRP) were increased in paediatric CD patients compared to adult CD patients ( p < 0.0001 and p = 0.01 , respectively). No significant differences were seen in ulcerative colitis (UC). In CD, baseline vitamin D levels ≥ 75 nmol/L and baseline CRP levels < 5 mg/L were associated with higher remission rate ( p = 0.02 ) at the end of follow-up. Moreover, aIBD patients had a higher risk of loss of response to biological therapy and treatment discontinuation compared to pIBD patients ( HR = 4.7 [1.6-13.4], p = 0.004 ). Conclusions. pCD patients had increased inflammation markers compared to aCD patients prior to biological treatment. In addition to this, vitamin D < 75 nmol/L and high CRP levels predicted poor response to treatment in IBD patients.
- 22 March 2022
- Published by Hindawi Limited in GastroHep
- Vol. 2022, 1-11
Open AccessPaediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment
Background. Recent epidemiological studies in inflammatory bowel disease (IBD) indicate that paediatric onset of IBD (pIBD) more often requires biological therapy compared to adult onset of IBD (aIBD). Whether this is due to a more aggressive disease phenotype or lower threshold of prescribing biologicals is unknown. In order to expand these findings in a clinical setting, we compared the inflammatory burden in pIBD and aIBD patients requiring biological therapy. Methods. We retrospectively included 70 pIBD and 83 aIBD patients initiating biological therapy. Symptoms and biomarker levels were recorded prior to and 6, 14, 22, and 52 weeks after initiation of biological therapy. Results. In Crohn’s disease (CD), the baseline levels of faecal calprotectin and C-reactive protein (CRP) were increased in paediatric CD patients compared to adult CD patients ( p < 0.0001 and p = 0.01 , respectively). No significant differences were seen in ulcerative colitis (UC). In CD, baseline vitamin D levels ≥ 75 nmol/L and baseline CRP levels < 5 mg/L were associated with higher remission rate ( p = 0.02 ) at the end of follow-up. Moreover, aIBD patients had a higher risk of loss of response to biological therapy and treatment discontinuation compared to pIBD patients ( HR = 4.7 [1.6-13.4], p = 0.004 ). Conclusions. pCD patients had increased inflammation markers compared to aCD patients prior to biological treatment. In addition to this, vitamin D < 75 nmol/L and high CRP levels predicted poor response to treatment in IBD patients.
- Open Access
- 24 April 2019
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 2 (1) , e12258
A Personalized eHealth Transition Concept for Adolescents With Inflammatory Bowel Disease: Design of Intervention
Background: Transfer from pediatric to adult care is a crucial period for adolescents with inflammatory bowel disease (IBD). Methods: Required transition skills and validated patient-reported outcome measures (PROMs) were identified via bibliographic search and clinical experience and were implemented into an existing eHealth program. Results: The following skills were identified: disease knowledge, social life, disease management, and making well-informed, health-related decisions. The PROMs included the following: self-efficacy (the IBD Self-Efficacy Scale—Adolescents), resilience (the 10-item Connor-Davidson Resilience Scale), response to stress (the Child Self-Report Responses to Stress—IBD), and self-management and health care transition skills (the Self-Management and Transition to Adulthood with Treatment questionnaire). Starting at age 14, the patient will be offered a 1-hour annual transition consultation with an IBD-specialized nurse. The consultation will be based on the results of the PROMs and will focus on the patient's difficulties. Patients will complete the PROMs on the eHealth program at home, allowing nurses and patients to prepare for the meeting. Symptom scores and medication will be filled out on the eHealth program to support disease self-management. The consultation will be a topic-centered dialogue with practical exercises. During routine outpatient visits with the provider, parents will be left out of half of the consultation when the patient is 16 years old; at 17 years old, the parents will not be present. At the transfer consultation, the pediatric provider, the adult gastroenterologist, the pediatric nurse, the patient, and the parents will be present to ensure a proper transfer. Conclusions: We have conducted a personalized eHealth transition concept consisting of basic elements that measure, train, and monitor the patients' transition readiness. The concept can be implemented and adjusted to local conditions.
- 24 April 2019
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 2 (1) , e12258
Open AccessA Personalized eHealth Transition Concept for Adolescents With Inflammatory Bowel Disease: Design of Intervention
Background: Transfer from pediatric to adult care is a crucial period for adolescents with inflammatory bowel disease (IBD). Methods: Required transition skills and validated patient-reported outcome measures (PROMs) were identified via bibliographic search and clinical experience and were implemented into an existing eHealth program. Results: The following skills were identified: disease knowledge, social life, disease management, and making well-informed, health-related decisions. The PROMs included the following: self-efficacy (the IBD Self-Efficacy Scale—Adolescents), resilience (the 10-item Connor-Davidson Resilience Scale), response to stress (the Child Self-Report Responses to Stress—IBD), and self-management and health care transition skills (the Self-Management and Transition to Adulthood with Treatment questionnaire). Starting at age 14, the patient will be offered a 1-hour annual transition consultation with an IBD-specialized nurse. The consultation will be based on the results of the PROMs and will focus on the patient's difficulties. Patients will complete the PROMs on the eHealth program at home, allowing nurses and patients to prepare for the meeting. Symptom scores and medication will be filled out on the eHealth program to support disease self-management. The consultation will be a topic-centered dialogue with practical exercises. During routine outpatient visits with the provider, parents will be left out of half of the consultation when the patient is 16 years old; at 17 years old, the parents will not be present. At the transfer consultation, the pediatric provider, the adult gastroenterologist, the pediatric nurse, the patient, and the parents will be present to ensure a proper transfer. Conclusions: We have conducted a personalized eHealth transition concept consisting of basic elements that measure, train, and monitor the patients' transition readiness. The concept can be implemented and adjusted to local conditions.
- Open Access
- 1 July 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (7) , 678-685
Genetic susceptibility and genotype–phenotype association in 588 Danish children with inflammatory bowel disease
To investigate the association between known inflammatory bowel disease (IBD)-associated genetic variants and development of paediatric IBD, and specific clinical sub-phenotypes. In this case-control study we included IBD patients <18 years of age at diagnosis from the Danish National Patient Registry and healthy children <18 years of age were randomly selected from the Danish Central Office of Civil Registration. The latter had filled out a questionnaire regarding health status, and DNA was obtained from blood samples and the buccal mucosa. Patient files were retrieved and clinical information was extracted. DNA was obtained from Guthrie cards from the Danish National Neonatal Screening Biobank (PKU-biobanken) at Statens Serum Institut and from blood samples. A total of 588 IBD patients (244 Crohn's disease (CD), 318 ulcerative colitis (UC) and 26 IBD-unclassified (IBDU)) and 543 healthy controls were included. We found an association between CD and rs22411880 (ATG16L1, odds ratio (OR)=1.7 [1.1-1.7], p=0.003), rs5743289 (NOD2, OR=1.4 [1.1-1.9], p=0.009) and the paediatric specific rs1250550 (ZMIZ1, OR=0.7 [0.5-0.9], p=0.01). None of the investigated 41 SNPs were associated with disease localisation, medical treatment or surgery after correcting for multiple analyses. We found an association between CD and three previously published genetic variants and replicated the association with the paediatric specific ZMIZ1 gene. No Bonferroni corrected significant genotype-phenotype associations were found. For future studies aimed at finding predictors for disease course in (paediatric) IBD, it will be worthwhile to include a combination of genetic, clinical and serological markers.
- 1 July 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (7) , 678-685
Open AccessGenetic susceptibility and genotype–phenotype association in 588 Danish children with inflammatory bowel disease
To investigate the association between known inflammatory bowel disease (IBD)-associated genetic variants and development of paediatric IBD, and specific clinical sub-phenotypes. In this case-control study we included IBD patients <18 years of age at diagnosis from the Danish National Patient Registry and healthy children <18 years of age were randomly selected from the Danish Central Office of Civil Registration. The latter had filled out a questionnaire regarding health status, and DNA was obtained from blood samples and the buccal mucosa. Patient files were retrieved and clinical information was extracted. DNA was obtained from Guthrie cards from the Danish National Neonatal Screening Biobank (PKU-biobanken) at Statens Serum Institut and from blood samples. A total of 588 IBD patients (244 Crohn's disease (CD), 318 ulcerative colitis (UC) and 26 IBD-unclassified (IBDU)) and 543 healthy controls were included. We found an association between CD and rs22411880 (ATG16L1, odds ratio (OR)=1.7 [1.1-1.7], p=0.003), rs5743289 (NOD2, OR=1.4 [1.1-1.9], p=0.009) and the paediatric specific rs1250550 (ZMIZ1, OR=0.7 [0.5-0.9], p=0.01). None of the investigated 41 SNPs were associated with disease localisation, medical treatment or surgery after correcting for multiple analyses. We found an association between CD and three previously published genetic variants and replicated the association with the paediatric specific ZMIZ1 gene. No Bonferroni corrected significant genotype-phenotype associations were found. For future studies aimed at finding predictors for disease course in (paediatric) IBD, it will be worthwhile to include a combination of genetic, clinical and serological markers.
- 1 October 2010
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (10) , 1196-1203
Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients
Infliximab dependency in children with Crohn's disease (CD) has recently been described and found to be associated with a decreased surgery rate. To assess infliximab dependency of adult CD patients, evaluate the impact on surgery, and search for possible clinical and genetic predictors. Two hundred and forty-five CD patients treated with infliximab were included from Danish and Czech Crohn Colitis Database (1999-2006). Infliximab response was assessed as immediate outcome, 1 month after infliximab start: complete, partial, and no response. Three months outcome, after last intended infusion: prolonged response (maintenance of complete/partial response), infliximab dependency (relapse requiring repeated infusions to regain complete/partial response or need of infliximab >12 months to sustain response). Forty-seven percent obtained prolonged response, 29% were infliximab dependent and 24% nonresponders. The cumulative probability of surgery 40 months after infliximab start was 20% in prolonged responders, 23% in infliximab-dependent patients and 76% in nonresponders (P<0.001). The cumulative probability of surgery at 40 months in patients on maintenance versus on demand regime was 33 and 31%, respectively (P=0.63). No relevant clinical or genetic predictors were identified. The infliximab dependency response seems to be equivalent to the prolonged response in adult CD patients when comparing surgery rates.
- 1 October 2010
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (10) , 1196-1203
Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients
Infliximab dependency in children with Crohn's disease (CD) has recently been described and found to be associated with a decreased surgery rate. To assess infliximab dependency of adult CD patients, evaluate the impact on surgery, and search for possible clinical and genetic predictors. Two hundred and forty-five CD patients treated with infliximab were included from Danish and Czech Crohn Colitis Database (1999-2006). Infliximab response was assessed as immediate outcome, 1 month after infliximab start: complete, partial, and no response. Three months outcome, after last intended infusion: prolonged response (maintenance of complete/partial response), infliximab dependency (relapse requiring repeated infusions to regain complete/partial response or need of infliximab >12 months to sustain response). Forty-seven percent obtained prolonged response, 29% were infliximab dependent and 24% nonresponders. The cumulative probability of surgery 40 months after infliximab start was 20% in prolonged responders, 23% in infliximab-dependent patients and 76% in nonresponders (P<0.001). The cumulative probability of surgery at 40 months in patients on maintenance versus on demand regime was 33 and 31%, respectively (P=0.63). No relevant clinical or genetic predictors were identified. The infliximab dependency response seems to be equivalent to the prolonged response in adult CD patients when comparing surgery rates.